Page 1 of 172
NSG 5240 ADVANCED PHARMACOLOGY
MIDTERM PRACTICE EXAM ALL COMPLETE 300
QUESTIONS WITH DETAILED SOLUTIONS JUST
RELEASED THIS YEAR
1. A patient is started on a medication that is a weak acid with a pKa of 4.4. In which part of the
body would this drug be MOST extensively absorbed?
A) Stomach (pH 1.5)
B) Duodenum (pH 6.0)
C) Jejunum (pH 7.4)
D) Colon (pH 8.0)
E) Oral mucosa (pH 6.5)
Answer: A Weak acids are best absorbed in acidic environments where they remain non-ionized
and lipid-soluble. In the stomach (pH 1.5), the drug is predominantly non-ionized and can readily
cross cell membranes.
2. A medication has a half-life of 24 hours and is administered once daily. Approximately how
many days will it take to reach steady-state concentration?
1
SUCCESS!
,Page 2 of 172
A) 1-2 days
B) 3-4 days
C) 5-6 days
D) 7-8 days
E) 9-10 days
Answer: C Steady-state is achieved after approximately 4-5 half-lives. With a 24-hour half-life,
steady-state is reached in about 5-6 days (120-144 hours).
3. Which pharmacokinetic parameter is MOST important in determining the frequency of drug
dosing?
A) Volume of distribution (Vd)
B) Clearance (Cl)
C) Bioavailability (F)
D) Half-life (t½)
E) Peak concentration
Answer: D Half-life determines the duration of drug action and the dosing interval. Drugs with
shorter half-lives require more frequent dosing to maintain therapeutic levels.
2
SUCCESS!
,Page 3 of 172
4. A patient with hepatic impairment is prescribed a medication that undergoes extensive first-
pass metabolism. What adjustment is MOST likely required?
A) Increased dose
B) Decreased dose
C) No dose change
D) Increased frequency
E) Increased route of administration
Answer: B First-pass metabolism occurs in the liver. Hepatic impairment reduces this
metabolism, increasing bioavailability and requiring a dose reduction to avoid toxicity.
5. Which of the following describes the movement of a drug from high to low concentration
without energy expenditure?
A) Active transport
B) Facilitated diffusion
C) Passive diffusion
D) Endocytosis
3
SUCCESS!
, Page 4 of 172
E) Pinocytosis
Answer: C Passive diffusion is the movement of drugs from an area of higher concentration to
lower concentration without energy expenditure or carrier proteins.
6. A drug has a high volume of distribution (Vd). This indicates that the drug:
A) Is primarily confined to the plasma
B) Is extensively distributed into tissues
C) Has poor tissue penetration
D) Is highly protein-bound
E) Is rapidly excreted
Answer: B A high Vd indicates that the drug is extensively distributed into tissues and is not
confined to the vascular compartment.
7. The therapeutic index of a drug is calculated as:
A) ED50 / TD50
B) TD50 / ED50
C) LD50 / ED50
4
SUCCESS!
NSG 5240 ADVANCED PHARMACOLOGY
MIDTERM PRACTICE EXAM ALL COMPLETE 300
QUESTIONS WITH DETAILED SOLUTIONS JUST
RELEASED THIS YEAR
1. A patient is started on a medication that is a weak acid with a pKa of 4.4. In which part of the
body would this drug be MOST extensively absorbed?
A) Stomach (pH 1.5)
B) Duodenum (pH 6.0)
C) Jejunum (pH 7.4)
D) Colon (pH 8.0)
E) Oral mucosa (pH 6.5)
Answer: A Weak acids are best absorbed in acidic environments where they remain non-ionized
and lipid-soluble. In the stomach (pH 1.5), the drug is predominantly non-ionized and can readily
cross cell membranes.
2. A medication has a half-life of 24 hours and is administered once daily. Approximately how
many days will it take to reach steady-state concentration?
1
SUCCESS!
,Page 2 of 172
A) 1-2 days
B) 3-4 days
C) 5-6 days
D) 7-8 days
E) 9-10 days
Answer: C Steady-state is achieved after approximately 4-5 half-lives. With a 24-hour half-life,
steady-state is reached in about 5-6 days (120-144 hours).
3. Which pharmacokinetic parameter is MOST important in determining the frequency of drug
dosing?
A) Volume of distribution (Vd)
B) Clearance (Cl)
C) Bioavailability (F)
D) Half-life (t½)
E) Peak concentration
Answer: D Half-life determines the duration of drug action and the dosing interval. Drugs with
shorter half-lives require more frequent dosing to maintain therapeutic levels.
2
SUCCESS!
,Page 3 of 172
4. A patient with hepatic impairment is prescribed a medication that undergoes extensive first-
pass metabolism. What adjustment is MOST likely required?
A) Increased dose
B) Decreased dose
C) No dose change
D) Increased frequency
E) Increased route of administration
Answer: B First-pass metabolism occurs in the liver. Hepatic impairment reduces this
metabolism, increasing bioavailability and requiring a dose reduction to avoid toxicity.
5. Which of the following describes the movement of a drug from high to low concentration
without energy expenditure?
A) Active transport
B) Facilitated diffusion
C) Passive diffusion
D) Endocytosis
3
SUCCESS!
, Page 4 of 172
E) Pinocytosis
Answer: C Passive diffusion is the movement of drugs from an area of higher concentration to
lower concentration without energy expenditure or carrier proteins.
6. A drug has a high volume of distribution (Vd). This indicates that the drug:
A) Is primarily confined to the plasma
B) Is extensively distributed into tissues
C) Has poor tissue penetration
D) Is highly protein-bound
E) Is rapidly excreted
Answer: B A high Vd indicates that the drug is extensively distributed into tissues and is not
confined to the vascular compartment.
7. The therapeutic index of a drug is calculated as:
A) ED50 / TD50
B) TD50 / ED50
C) LD50 / ED50
4
SUCCESS!
